6th Edition of Cardiology World Conference
September 15-17, 2025 | London, UK
Ventricular Quadrigeminy
Ventricular quadrigeminy is an unusual cardiac rhythm disorder characterized by a distinctive pattern in which every fourth heartbeat is a premature ventricular contraction (PVC). Unlike the regular rhythm seen in a healthy heart, ventricular quadrigeminy introduces a disruption with these premature contractions arising from the ventricles. This unique four-beat sequence sets it apart from typical cardiac rhythms. While the immediate health risks of ventricular quadrigeminy might be limited, it can signal an underlying heart condition, prompting the need for further assessment by a healthcare professional. The use of electrocardiograms (ECGs) is pivotal in monitoring and comprehending the cardiac rhythm, allowing for the identification and management of ventricular quadrigeminy to maintain optimal heart health.
Robert J Chilton
University of Texas Health Science Center San Antonio, United States
Gustavo Lionel Knop
Mayo Clinic, United States
Sekib Sokolovic
Sarajevo School of Science and Technology, Medical Faculty, ASA Hospital, Bosnia and Herzegowina
Arthur J Siegel
Massachusetts General Hospital, United States
Iris Panagiota Efthymiou
University of Greenwich, United Kingdom
Thomas Bernd Dschietzig
Relaxera GmbH & Co. KG, Germany
Y J H J Taverne
Erasmus University Medical Center, NetherlandsSubmit your abstract Today
Title : Novel ways of cardiovascular risk assessment
Syed Raza, Awali Hospital, Bahrain
Title : Empathy and precision: Revolutionizing communication between cardiologists and patients
Iris Panagiota Efthymiou, University of Greenwich, United Kingdom
Title : Use of SGLT2-i in treatment of established Coronary Artery Disease (CAD) in diabetic patients
Arva Zahid, University Hospitals Birmingham, United Kingdom
Title : Use of SGLT2-i in treatment of established Coronary Artery Disease (CAD) in diabetic patients
Arva Zahid, University Hospitals Birmingham, United Kingdom
Title : Use of SGLT2-i in treatment of established Coronary Artery Disease (CAD) in diabetic patients
Arva Zahid, University Hospitals Birmingham, United Kingdom
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany